CYSTATIN C, DIABETIC KIDNEY DISEASE, AND IMPLICATIONS FOR DIABETES MANAGEMENT.

Lesley A Stevens, Josef Coresh, Christopher H Schmid, Harold I Feldman, Marc Froissart, John Kusek, Jerome Rossert, Frederick Van Lente, Robert D Bruce III, Yaping Lucy Zhang, Tom Greene, Andrew S Levey, None, Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD American Journal of Kidney Diseases. ,vol. 51, pp. 395- 406 ,(2008) , 10.1053/J.AJKD.2007.11.018

Michael G. Shlipak, Monica D. Mattes, Carmen A. Peralta, Update on Cystatin C: Incorporation Into Clinical Practice American Journal of Kidney Diseases. ,vol. 62, pp. 595- 603 ,(2013) , 10.1053/J.AJKD.2013.03.027

Vikas R. Dharnidharka, Charles Kwon, Gary Stevens, Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis American Journal of Kidney Diseases. ,vol. 40, pp. 221- 226 ,(2002) , 10.1053/AJKD.2002.34487

Michael G. Shlipak, Kunihiro Matsushita, Johan Ärnlöv, Lesley A. Inker, Ronit Katz, Kevan R. Polkinghorne, Dietrich Rothenbacher, Mark J. Sarnak, Brad C. Astor, Josef Coresh, Andrew S. Levey, Ron T. Gansevoort, Cystatin C versus creatinine in determining risk based on kidney function. The New England Journal of Medicine. ,vol. 369, pp. 932- 943 ,(2013) , 10.1056/NEJMOA1214234

S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, D. R. Matthews, Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. ,vol. 35, pp. 1364- 1379 ,(2012) , 10.2337/DC12-0413

Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Robert R. Henry, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit, Guillermo E. Umpierrez, CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. Endocrine Practice. ,vol. 22, pp. 84- 113 ,(2016) , 10.4158/EP151126.CS

W. Timothy Garvey, Jeffrey I. Mechanick, Elise M. Brett, Alan J. Garber, Daniel L. Hurley, Ania M. Jastreboff, Karl Nadolsky, Rachel Pessah-Pollack, Raymond Plodkowski, , AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocrine Practice. ,vol. 22, pp. 1- 203 ,(2016) , 10.4158/EP161365.GL

George L. Bakris, Mark E. Molitch, Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What’s the Fuss? Diabetes Care. ,vol. 39, pp. 1287- 1291 ,(2016) , 10.2337/DC15-2534

Maryam Afkarian, Leila R. Zelnick, Yoshio N. Hall, Patrick J. Heagerty, Katherine Tuttle, Noel S. Weiss, Ian H. de Boer, Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014 JAMA. ,vol. 316, pp. 602- 610 ,(2016) , 10.1001/JAMA.2016.10924

, O. B. Crofford, I. L. Spratt, A. L. Drash, F. R. Ruhland, D. I. Bell, Statement on Hypoglycemia Diabetes Care. ,vol. 5, pp. 72- 73 ,(1982) , 10.2337/DIACARE.5.1.72